Epsilon Bioconsulting Limited is a boutique biotechnology and pharmaceutical consultancy offering a broad range of services to clients ranging from scientific consultancy, to bespoke education-based projects to working with clinical development, medical affairs and marketing teams to support product development.
Charles Owen, a PhD scientist with significant experience working in the pharmaceutical and biotechnology industry, leads the consultancy. During his time at Novartis, he was responsible for the scientific support of omalizumab (Xolair), a therapeutic monoclonal antibody, which remains the only significant new therapeutic for the treatment of asthma launched in the last 40 years.
Charles has amassed significant experience of drug discovery, drug development and post-launch marketing support and is now able to offer these services to both small and larger clients.
The development of biologics like antibodies and other protein therapeutics is increasingly recognized as a highly specialized discipline.
The aim of Epsilon Bioconsulting is to act as a key expert partner helping businesses navigate the discovery and development of biological products.
Epsilon Bioconsulting Limited works with both large and small life science companies, from early discovery to peri- and post-product launch activities, as well as portfolio review. We are also able to offer support for investment decision-making for institutions considering entry to the therapeutic antibody field.
Charles Owen
Landline: (+44) 1444 226320
Mobile: (+44) 7748704654
charlie@epsilonbioconsulting.co.uk
July 2014 • present
Providing consulting services to biotechnology and pharmaceutical industry. Specific expertise in:
April 1996• June 2014
2009 - 2014
Novartis Institutes for BioMedical Research lead representative for asthma biologics global project teams with responsibility for all pre-clinical research activities including:
- Regulatory submissions / interactions (IND, IMPD, Health Authority submissions documentation including approvals (EU, FDA, PMDA), Paediatric Investigational Plans etc)
- Key development experience of projects including:
• Omalizumab (Xolair) – anti-IgE mAb: Ph2 (1998) – Post-marketing support (2014)
• Ligelizumab (QGE031 – 2006-2014) – high-affinity anti-IgE mAb (Ph2 asthma)
• QAX576 (anti-IL-13 mAb): 2011-2014
• AIN457 (anti-IL-17a in severe asthma – PoC): 2011-2014
• QBX258 (Undisclosed anti-cytokine combination therapy)
• Member of expert panels
• Cross disease area and cross-indication experience and expertise
2008• 2014
Developed and led initiatives aimed at improving antibody delivery to the lung.
This included working with cross-functional teams to investigate:
• Pulmonary delivery of proteins, antibodies and peptides
• Targeted delivery of proteins and antibodies to the lung through transcytotic mechanisms
2000• 2009
Highly experienced drug discovery and development scientist with proven track-record of delivering drugs ready for clinical development. Extensive experience of leading multiple cross-disciplinary project teams conducting new drug discovery
1996• 2006
Responsible for a laboratory of molecular cell biologists and immunologists.
• Member of Respiratory Franchise Business Development and Licensing team
• Member of Respiratory Diseases therapeutic area strategy team
• Published over 30 scientific papers and patents
• Regular speaker at allergy and respiratory disease meetings and congresses
1992•1996
Cancer Research UK (London): Transcriptional regulation of the murine surfeit gene locus.
1989•1992
University of Glasgow: Transcriptional regulatio
2005
Warwick Business School: Dissertation: Measuring productivity in innovation-led industries.
Epsilon Bioconsulting Limited offers services in the following areas:
Epsilon Bioconsulting welcomes enquiries -
please use the form below to contact Charles: